“Blinatumomab was granted accelerated approval for the treatment of adults and children with B-cell precursor (BCP) acute lymphoblastic leukemia.”
“In April 2020, the FDA approved selumetinib for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas”